Press Releases

21 August 2013
Karus Therapeutics secures prominent role in epigenetics debate at SciBX Summit 2013

Oxford, UK, 21 August 2013 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced its engagement with the “Epigenetics’ Second Wind” debate at the SciBX Summit on Innovation in Drug Discovery and Development to be held in Boston, USA, on 29-30 October.

Karus is at the forefront of developing innovative, potent and selective HDAC6 inhibitors for the treatment of inflammatory diseases and cancer. Given the Company’s focus on this important target, the Company is pleased to play a prominent role in this thought-leading event that is being organised jointly by the leading publications BioCentury and Nature. During the three-hour debate, Karus’s CEO Dr Simon Kerry will join key stakeholders from biotech, pharma, academia and the investment community in creating a roadmap for solving key translational issues in the discovery and development of a new generation of epigenetic drugs – a significant output of the meeting.

Commenting on the importance of epigenetic therapeutics Dr Kerry said: “Recent epigenetic research has created valuable therapeutic insights, with isoform-selective HDAC inhibitors at the forefront of this new wave. Karus’s focus on the development of highly potent and selective HDAC6 inhibitors for the treatment of inflammatory diseases and cancer, combined with a strong investor base that is committed to the clinical development of these innovative drugs, places the company at the vanguard of R&D against this emerging target.”

He added: “During the course of developing our HDAC6 programme we have accumulated a wealth of knowledge and insights and, with this valuable experience, we look forward to making a significant contribution towards the roadmap for this fast evolving area.”

Karus has two proprietary programmes focused on the development of innovative medicines for the treatment of inflammation and cancer, one based on the potent and isoform-selective inhibition of HDAC6 and the other focused on dual-selective inhibitors of PI3K p110δ and p110β.